Clinical Trial: Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07614646) titled 'Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients' on May 20.

Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) combination with Ivonescimab in patients with sq-NSCLC.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Squamous Non-Small Cell Lung Cancer sqNSCLC

Intervention: BIOLOGICAL: EVM14

Cancer Vaccine, Intramuscular (IM) injection at escalating dose levels, administered once every 3 weeks (Q3W)

BIOLOGICAL: Ivo...